Evidence map›Paper›PMID 41465326›Full record

ArticleInternational journal of molecular sciences2025

Bioinformatic Approach to Identify Potential

Sanjive Qazi, Stephen Richardson, Mike Potts, Scott Myers, Saran Saund, Tapas De, Vuong Trieu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sanjive QaziOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Stephen RichardsonOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Mike PottsOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Scott MyersOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Saran SaundOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Tapas DeOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Vuong TrieuOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian carcinoma is the most common and aggressive form of ovarian cancer, accounting for over 60% of cases and nearly 75% of deaths, mainly due to late diagnosis and tumor aggressiveness. Standard treatment is platinum-based chemotherapy with paclitaxel, but relapse is frequent. This study aimed to identify prognostic biomarkers for patients with poor survival outcomes after Taxol treatment using bioinformatics analysis. We examined the effects of

Indexed as

Antineoplastic Agents, PhytogenicBiomarkers, TumorComputational BiologyOvarian NeoplasmsPaclitaxelTransforming Growth Factor beta2FemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisRNA, MessengerAntineoplastic Agents, PhytogenicBiomarkers, TumorPaclitaxelRNA, MessengerTGFB2 protein, humanTransforming Growth Factor beta2biomarkerovarian cancerpaclitaxelprognosistransforming growth factorstumor microenvironment

Identifiers

PMID41465326
PMCPMC12733110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.